XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

NCT05970302 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Tislelizumab
Bevacizumab
Oxaliplatin
Capecitabine
MSS/pMMR
Metastatic Colorectal Cancer (mCRC)
RAS-mutated
First-Line

Interventions

DRUG: Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences